Continuing in this well-attended annual event, OCTANe will host its annual Orange County Ophthalmology Technology Summit (OTS) on June 28, 2019.
As in years past, OTS will be held at Fashion Island Hotel in Newport Beach.
The meeting is billed as a local forum where leading ophthalmology technologists, researchers, clinicians, and entrepreneurs can come together to discuss ground-breaking ophthalmic technologies, unmet clinical needs, and new business opportunities all to fuel the ophthalmology ecosystem in Orange County, California.
The website for the meeting is here: www.ots2019.com.
As a reminder, October 29th and 3oth will see the commencement of the annual Medical Technology Innovation Forum (MTIF), hosted by OCTANe. This year, MTIF is being held at Newport Beach Marriott Hotel & Spa.
MTIF is billed as the largest conference in Southern California focused on high-growth medtech innovation and investment. Over 850 attendees are advertised, ranging from entrepreneurs, industry executives, strategic partners, qualified investors and academicians, and with attendees of this scope and nature, MTIF is said to bring the entire ecosystem together for a two-day content rich forum.
The website for the meeting is here: https://www.mtif2018.com/.
As reported by Law360 at URL: https://www.law360.com/ip/articles/1085124/ptab-upholds-alcon-patent-for-glaucoma-treatment
The Final Written Decision itself is included below, and can be downloaded by clicking this link:
The patent may be viewed at the USPTO website at
PTAB Upholds Alcon Patent For Glaucoma Treatment
Law360 (September 21, 2018, 8:52 PM EDT) — The Patent Trial and Appeal Board on Thursday upheld the validity of an Alcon patent covering the glaucoma treatment Travatan Z, rejecting arguments by generics maker Argentum that the invention was obvious.
The board held that Argentum Pharmaceuticals LLC failed to establish that a combination of publications and patents that preceded Alcon Research Ltd.’s patent would have made the challenged patent claims obvious for an ordinarily skilled artisan, according to the final written decision. Continue reading
Last month, it was reported that Glaukos filed a lawsuit against Ivantis, alleging that the Ivantis Hydrus Microstent device infringes on patents held by Glaukos covering its iStent® devices. See “Glaukos Sues Ivantis over patents on iStent® Devices”.
Ivantis has now launched a response: In a filing on May 23, 2018, Ivantis has petitioned the USPTO to invalidate one of the two patents asserted by Glaukos in its lawsuit. Continue reading
The 4th annual Med Tech Monday will this year be held at the Avenue of the Arts Hotel in Costa Mesa, on August 6, 2018.
Advertised as a one-day medical device conference, the conference aims to provide Orange County with the latest medical device innovations, investment insights, startups and discussions with industry leaders as to where the industry is headed through the end of the year. The conference will include presentations and speakers as well as a sponsor exhibit area.
Topics at this year’s conference are said to include: Continue reading
OCTANe is holding its annual Technology Innovation Forum (TIF 2018) on Thursday and Friday, May 31 and June 1, 2018, at the Newport Beach Marriott Hotel & Spa.
According to OCTANe, its annual TIF is the largest conference in Southern California focused on high growth and innovation technology investment. “With nearly 800 attendees and dozens of companies and investors, it has become a must-attend event for tech executives, entrepreneurs and investors.”
Details and registration are available at https://www.tif2018.com.
April 25, 2018: OCTANe today announced enhancements to its annual Ophthalmology Technology Summit, OTS 2018, which is currently scheduled for Friday, June 29, 2018 at the Fashion Island Hotel, Newport Beach.
According to the announcement, OCTANe said that it had partnered with the CEDARS/ASPENS Society to enhance offerings around ophthalmic surgery for OTS 2018. Details and registration for OTS 2018 are available at www.ots2018.com.
The announcement continued: Continue reading
April 17, 2018: Glaukos Corporation of San Clemente, CA, has filed a patent infringement lawsuit against Ivantis, Inc. of Irvine, CA. The lawsuit was filed April 14, 2018.
The patents involved are:
U.S. Patent No. 6,626,858 (Lynch et al.), “Shunt Device and Method For Treating Glaucoma”
U.S. Patent No. 9,827,143 (Lynch et al.), “Shunt Device and Method For Treating Ocular Disorders”
In its Complaint, Glaukos alleges that the Ivantis Hydrus Microstent device infringes on patents held by Glaukos covering its iStent® devices.
At one time, the public record easily accessible from the PTO gave only the barest abstract of title. Assignor, Assignee, date of recordation, reel and frame numbers: that was it.
It was possble to visit the PTO and obtain a copy of the Assignment document, as recorded on microfilm, but the process was cumbersome and time-consuming.
No more. A few years ago, the PTO made it easy to obtain a copy of the actual Assignment document. Continue reading
March 1, 2018: The USPTO today published a patent application filed by Imprimis Pharmaceuticals of San Diego, CA: U.S. Application Publication No. 2018/0055790, “Epinephrine-Based Ophthalmic Compositions for Intraocular Administration and Methods for Fabricating Thereof”.
According to the published abstract:
Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.
Published Claim 1 recites:
1. A method for preparing a pharmaceutical composition, the method comprising:
(a) preparing an aqueous composition consisting of:
(a1) a therapeutically effective quantity of at least one compound selected from the group consisting of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide;
(a2) at least one metal chelator;
(a3) optionally, at least one anesthetic;
(a4) optionally, at least one non-steroid anti-inflammatory drug; and
(a5) a quantity of sterile water, wherein the composition is optionally free of sulfites and is free of preservatives; and
(b) lyophilizing the aqueous composition, to obtain thereby the lyophilized pharmaceutical composition.
The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20180055790.
Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is simply a copy of the as-filed application, without examination.